FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1531-1532 April 6, 2006 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article Related Article by Pagès, F. PubMed Citation

To the Editor: Pagès and coworkers (Dec. 22 issue)¹ described the critical importance of the presence of CD45RO+ cells for prevention of early progressive disease in patients with colorectal cancer.

Most CD4+CD25+ regulatory T cells express CD45RO and are expanded in epithelial cancers.² Therefore, we wonder why the authors did not comment on the role of CD4+CD25+ regulatory T cells in their patients. Our own data suggest that a high content of intratumoral CD4+CD25+ regulatory T cells in ovarian cancer is associated with a poor prognosis.³

Dominik Wolf, M.D.
Christian Marth, M.D., Ph.D.
Anna Maria Wolf, M.D.
Innsbruck Medical University
. . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.